Guillain-Barre Syndrome (GBS) following viral vector COVID-19 vaccination (AstraZeneca) : a case report
DOI:
https://doi.org/10.14456/dcj.2023.39Keywords:
Guillain-Barre Syndrome: GBS, AstraZeneca, Adverse events following immunization: AEFI, SARS-CoV-2Abstract
Guillain-Barré Syndrome (GBS) is an immune-mediated polyneuropathy characterized by progressive symmetrical ascending paralysis of limbs and decreased or absent of deep tendon reflexes. Diagnostic workup of cerebrospinal fluids demonstrated albuminocytologic dissociation with confirmatory evidence of early demyelinating electrodiagnostic feature on nerve conduction study. The etiology of GBS is not yet clear, but it typically occurs in the post bacterial or viral infection such as Parainfluenza virus, Herpes virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Campylobacter jejuni, Mycoplasma pneumoniae, Haemophilus influenza, etc. In addition, GBS can occur after surgery, traumatic injury, and vaccination (adverse events following immunization; AEFI). We report case of a 28-year-old Thai male without comorbidity presenting with progressive numbness and weakness of both hands and feet two days after being given viral vector (AstraZeneca) COVID-19 vaccine. He received intravenous immunoglobulin (IVIg) for 5 days until fully recovery. Therefore, if there are no restrictions to access the alternative vaccine, the patient should be given a booster dose of vaccine other than viral vector platform and adequate advice about GBS from any COVID-19 vaccines under limited information.
Downloads
References
U.S. Food and Drug Administration. Emergency Use Authorization [Internet]. U.S. Food and Drug Administration; 2022 [cited 2022 Sep 20]. Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#vaccines
World Health Organization. The different types of COVID-19 vaccines [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Nov 25]. Available from: https://www.who.int/news-room/feature-stories/detail/the-race-for-a-covid-19-vaccine-explained
Thai Food and Drug Administration. Details of medicinal product: Vaxzevria [Internet]. Nonthaburi: Thai Food and Drug Administration; 2022 [cited 2022 Sep 20]. Available from: http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drugex.aspx?Newcode=U1DR1C10726 40000111C (in Thai)
Division of Communicable Disease, Department of Disease Control (TH). Guidelines for vaccination against COVID-19 in Thailand’s epidemic situation in 2021. 2nd ed. Nonthaburi: Division of Communicable Disease, Department of Disease Control (TH); 2021. (in Thai)
Bureau of Epidemiology, Department of Disease Control (TH). Guidelines for monitoring and investigation of adverse events following immunization of COVID-19 vaccines [Internet]. Nonthaburi: Bureau of Epidemiology, Department of Disease Control (TH); 2021 [cited 2022 Sep 20]. Available from: https://appsdoe.moph.go.th/boe/software/file/Guideline_AEFI_COVID19vaccine_DOE_17062021.pdf (in Thai)
Council for International Organizations of Medical Sciences, World Health Organization (WHO). Definition and application of terms for vaccine pharmacovigilance: Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Geneva: World Health Organization; 2012.
package leaflet. COVID-19 Vaccine AstraZeneca [Package insert]. [Internet]. [cited 2022 Feb 2]. Available from: https://www.azcovid-19.com/content/dam/azcovid/pdf/thailand/th-epil-azd1222-en.pdf
Keh RYS, Scanlon S, Datta-Nemdharry P, Donegan K, Cavanagh S, Foster M, et al. COVID-19 vaccination and Guillain-Barre syndrome: analyses using the National Immunoglobulin Database. Brain. 2022;146(2):739-48. doi: 10.1093/brain/awac067.
McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150-63. doi: 10.1159/000184748.
Kasemsap N, Vorasoot N, Kongbunkiat K, Tiamkao S, Chotmongkol V, Sawanyawisuth K, et al. The epidemiology of Guillain-Barré syndrome in Thailand over 13 years (2005-2017): a nationwide population-based retrospective cohort study. J Peripher Nerv Syst. 2021;26(2):202-8. doi: 10.1111jns.12453.
Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain-Barr ́e syndrome in ten steps, Nat Rev Neurol. 2019;15(11):671-83. doi: 10.1038/s41582- 019- 0250-9.
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397 (10280) :1214-28. doi: 10.1016/S0140-6736(21)00517-1.
Khan F, Sharma P, Pandey S, Sharma D, V V, Kumar N, et al. COVID‐19‐associated Guillain‐Barre syndrome: postinfectious alone or neuroinvasive too?. J Med Virol. 2021;93(10) :6045-9. doi: 10.1002/jmv.27159.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045) :717-27. doi: 10.1016/S0140-6736(16) 00339-1.
Aly AS, Alkolfat F, Mansour ER, Salama S. Guillain-Barre syndrome following COVID-19 vaccination: a case report and an updated review. Neuroimmunology Reports. 2022;2:100083. doi: 10.1016/j.nerep.2022.100083.
American Academy of Neurology. Immunotherapy for Guillain-Barre Syndrome management [Internet] Minneapolis, MN: The American Academy of Neurology; 2022. [cited 2022 Feb 2] Available from: https://www.aan.com/Guidelines/home/GuidelineDetail/59.
Martin Arias LH, Sanz R, Sainz M, Treceño C, Carvajal A. Guillain-Barré syndrome and influenza vaccines: a meta-analysis. Vaccine. 2015; 33(31):3773-8. doi: 10.1016/j.vaccine. 2015. 05.013.
Vellozzi C, Iqbal S, Stewart B, Tokars J, DeStefano F. Cumulative risk of Guillain-Barre syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic. Am J Public Health. 2014;104 (4):696-701. doi: 10.2105/AJPH.2013. 301651.
Principi N, Esposito S. Vaccine-preventable diseases, vaccines and Guillain-Barre syndrome. Vaccine. 2019;37(37):5544-50. doi: 10.1016/ j.vaccine.2018.05.119.
European Medicine Agency. COVID-19 vaccine safety update [Internet]. 2021 [cited 2021 Nov 25]. Available from: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-AstraZeneca-8-september-2021_en.pdf
Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021;90(2):315-18. doi: 10.1002/ana.26144.
Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 2021;14 (4):e242956. doi: 10.1136/bcr-2021-242956.
Finsterer J. Exacerbating Guillain-Barré syndrome eight days after vector-based COVID-19 vaccination. Case Rep Infect Dis. 2021;2012: 3619131. doi: 10.1155/2021/3619131.
World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barre Syndrome (GBS) following adenovirus vector COVID-19 vaccines [Internet]. Geneva: World Health Organization; 2021. [cited 2021 Nov 25]. Available from: https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs
Galvez LA, Abadia R, Guevara R, Orozco H. Guillain-Barre syndrome after vaccination for COVID-19. The first report in Latin America. Neurology Perspectives. 2021;1(4):236-8. doi: 10.1016/j.neurop.2021.09.002.
Matarneh AS, Al-Battah AH, Farooqui K, Ghamoodi M, Alhatou M. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clin Case Rep. 2021;9 (9):e04756. doi: 10.1002/ccr3.4756.
Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021; 27(12):2144-53. doi: 10.1038/s41591- 021-01556-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Disease Control Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the Disease Control Journal are considered as academic work, research or analysis of the personal opinion of the authors, not the opinion of the Thailand Department of Disease Control or editorial team. The authors must be responsible for their articles.
.png){kind=logo}
